IP Verse

Eliglustat (Genz 112638) As Inhibitor Of Glucosylceramide Synthase For Use In A Method Of Treating Fabry'S Or Gaucher'S Disease, The Method Comprising Adjusting The Individual Therapeutical Dose To The P-450 Metabolism Of The Patient - EP3133070

EP3133070

GENZYME
Application Number
EP16175117A
Filing Date
Nov 24, 2010
Status
Granted And Under Opposition
Jul 12, 2019
Grant Date
Aug 14, 2019
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3137497B2
EP2976359B2
EP2970843B1

Bibliography

The patent EP3133070B1 was granted to Genzyme on Aug 14, 2019 following the initial filing on Nov 24, 2010 under the application number EP16175117A . The current legal status of the patent is Granted And Under Opposition.

Patent Summary

Patent Family New

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ACCORD HEALTHCAREMay 14, 2020ADMISSIBLE
HETERO LABSMay 14, 2020ADMISSIBLE
TEVA PHARMACEUTICALSMay 13, 2020ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents